You are here

  • Home
  • Archive
  • Volume 10, Issue 5
  • Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Citation Tools

Article menu
Clinical/translational cancer immunotherapy
Original research
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Gomez-Roca C, Cassier P, Zamarin D, et al
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Journal for ImmunoTherapy of Cancer 2022;10:e004076. doi: 10.1136/jitc-2021-004076